摘要
目的探讨伊立替康联合铂类治疗复发性卵巢癌的临床效果。方法选取2009年2月至2011年3月因复发性卵巢癌就诊于辽河油田第二职工医院进行治疗的患者122例,用完全随机法分为两组:联合用药组(61例)采用伊立替康联合铂类化疗方案,伊立替康组(61例)采用伊立替康治疗,统计分析两组患者的治疗效果以及并发症情况。结果联合用药组患者总有效率为75.4%,显著优于伊立替康组,比较差异有统计学意义(P<0.05)。联合用药组患者主要不良反应为消化道症状(73.8%)以及骨髓抑制症状(52.5%),其发生率及严重程度均显著高于伊立替康组,比较差异有统计学意义(P<0.05)。结论伊立替康联合铂类化疗方案治疗复发性卵巢癌具有较好疗效,值得临床推广应用。
Objective To discuss the clinical effect of irinotecan combined with platinum chemotherapy for the treatment of recurrent ovarian cancer. Methods From Feb. 2009 to Mar. 2011,122 patients with recurrent ovarian cancer in the Second Workers＇ Hospital of Liaohe Oilfield were randomly divided into combined treatment group（ irinotecan combined with platinum chemotherapy group, n = 61 ）and irinotecan groupirinotecan group, n =61 ）. The curative effect and the complications of patients were summarized and a statistical analysis for the results was made. Results In the combined treatment group, the total effective rate was 75.4% ,which was significantly better than the irinotecan group with statistically significant difference （P 〈 0.05 ）. In the combined treatment group, the major adverse reactions were gastrointestinal symptoms （73.8%） and bone marrow suppression symptoms（52.5% ）, the severity and its incidence were significantly higher than the irinoteean group,with statistically significant difference （P 〈 0. 05 ）. Conclusion Irinoteean combined with platinum chemotherapy for the treatment of recurrent ovarian cancer has a better curative effect,which is worth of clinical application and promotion.
出处
《医学综述》
2014年第11期2107-2108,共2页
Medical Recapitulate
关键词
伊立替康
铂类
化疗
复发性卵巢癌
Irinoteean
Platinum
Chemotherapy
Recurrent ovarian cancer
